SUMEET SHARMA

Pharma India is not only Rx - it’s Gx and OTC as well (and much more) and all are huge market contributors. I am dwelling into few newer learning this week with exposure to Gx & OTC . But before that I made sure that I’m on the right knowledge quotient for Gx & OTC in pharma. Ping me on PW to know more. #Rx #Gx #OTC #Pharma #Training #Learninganddevelopment #Salestraining

Great contribution by Indian Pharma sector to our country and Global population ( including US ). Dt 2.5.2024 ****** Humble Contribution to US with yearly savings : US : $219Bn in 2022 and $1.3Tn between 2013 and 2022 - our sector still striving hard to increase basket of drugs and unmet quality improvements , if any. **** Provide Indian pharmaceutical companies supply a substantial proportion of drugs to U.S. residents, with four out of ten of all prescriptions filled in the U.S. in 2022 being supplied by Indian companies Indian companies supplied 47% of all generic prescriptions filed in the U.S. and 15% of the volume of biosimilars. Out of the top 10 therapy areas by prescription volume, Indian companies supplied more than half of the prescriptions for five: hypertension, mental health, lipid regulators, nervous system disorders, and antiulcerants Overall, medicines from Indian companies provided $219Bn in savings to the U.S. healthcare system in 2022 and a total of $1.3Tn between 2013 and 2022. ---- Source IQVIA Institute for Human Data Science

📢 Kind Attention to All Pharmaceutical Innovators ( Supply Chain Managers, Procurement Managers, Import Managers) in my connection! We are thrilled to present the comprehensive product list from our esteemed supplier (Precise Biopharma - India) . As your trusted partner in pharmaceutical excellence, we offer an extensive range of high-quality Active Pharmaceutical Ingredients (APIs) to elevate your drug development process. 🌟 Attached Our Product Portfolio: 📄 Why Partner with Us? 1 - Uncompromised Quality: Each API is meticulously tested to ensure the highest standards of purity and efficacy. 2 - Regulatory Compliance: All products meet stringent regulatory requirements, facilitating smooth approval processes. 3 - Global Reach: Our supplier network ensures reliable delivery to meet your production timelines. 4 - Technical Support: Access to comprehensive documentation and expert guidance for seamless integration into your formulations. 🤝 Let’s Collaborate: We're here to help you achieve your pharmaceutical goals. Connect with us to discuss your specific needs and how our high-quality APIs can drive your success. Qummer Khan E-BDM Synapse Chemical WhatsApp : +923210199910 Email: Bizdev2@synapse-chems.com . . . . . #Pharmaceuticals #API #DrugDevelopment #PharmaInnovation #QualityAssurance #RegulatoryCompliance #PharmaPartnership #importmanagers #procurement #supplychain #productdevelopment

India's pharmaceutical industry has witnessed remarkable growth in the last 15 years, with an explosion of generic brands surpassing ₹100 crore in sales. These brands now account for 44% of the domestic formulation market valued at around ₹2 lakh crore, outpacing market growth rates. In FY09, there were 21 brands with over ₹100 crore in sales, a number that escalated to 388 brands in FY24, marking an impressive 18-fold increase. Moreover, domestic formulation manufacturers have attracted substantial investments, including strategic and private equity deals totaling over $14 billion in the past 6 years. #Pharmaceuticals #India #pharmamarketGrowth #pharmaindia #pharmabrands #Indianpharma Source : The Economic Times

Recently I came across many news reports based on McKinsey-IPA report, which said that outcomes of USFDA inspections of Indian pharmaceutical manufacturers in year 2023 were better as compared to global counterparts. These reports said 13% of inspections in India were classified as OAI as compared global 15%. The report also said that percentage of OAI in India in 2023 was half of OAI percentage in 2014. While the percentages for 2014 and 2023 are correct, if one look at 15 year in FDA data base, it shows lot of fluctuations to arrive at any conclusion about improvement in compliance because the data doesn't show declining trend. (See attached trend chart. Numbers are slightly different because I used filter to include drugs, devices and biologicals) Also FDA quality report for 2023 explains that 80% of 96 warning letters issued in 2023, were issued to OTC firms which contributed to only 20% inspections and 50% of those warning letters were issued to disinfectant manufacturers due to EG and DEG contamination. This is not a usual situation and hence the conclusion that OAI rate in India was lower than global rate is not accurate.

India's pharma exports rise 10% to $27.9 bn in FY24 💊 🏥 ⚕ In the fiscal year 2023-24, India's pharmaceutical exports surged by 9.67%, reaching USD 27.9 billion, showcasing robust growth despite a 3% dip in total exports. March alone witnessed a noteworthy 12.73% increase, totaling USD 2.8 billion, as per commerce ministry data. This momentum builds upon the previous fiscal's export figures of USD 25.4 billion. The sector's top export markets include the US, the UK, the Netherlands, South Africa, and Brazil, with the US alone constituting over 31% of India's pharma exports, followed by the UK and the Netherlands, each around 3%. Notably, India's pharmaceutical exports expanded into new territories such as Montenegro, South Sudan, Comoros, and Brunei, signaling the industry's increasing global footprint. With experts foreseeing India's pharmaceutical business to potentially surpass $130 billion by 2030, driven by burgeoning market opportunities and heightened overseas demand, the industry's current worth of over $50 billion in 2022-23 may just be the beginning. Monthly, India consistently exports pharmaceutical products worth USD 2-3 billion, highlighting its sustained contribution to the global healthcare market. As the third-largest pharmaceutical industry by volume and 13th largest by value globally, India produces an extensive range of over 60,000 generic drugs across 60 therapeutic categories. To bolster domestic manufacturing, the government has introduced two production-linked incentive (PLI) schemes targeting key pharmaceutical ingredients and generic medicines. These initiatives underscore India's commitment to not only meet domestic demand but also solidify its position as a pharmaceutical powerhouse on the global stage. #pharmamanufacturing #pharmaindustry #sunpharma #glenmarkpharma #cipla #pharmaceuticalsales #customsynthesis

Discover the perspectives of Mehul Shah, Founder of Shah TC, on the modernization of the pharma distribution business in India, with a special focus on serving North Indian customers. #PharmaDistribution #ModernPharma #HealthcareDistribution #PharmaBusiness #MehulShah #ShahTC #PharmaIndustry

Bulk Drugs and Drug Intermediates #Imports Set to #Drop by #12% in FY24 The #growth projections for the Indian pharma industry during FY24 and FY25, estimated at 7%-9%, will drive #incremental #requirements for #APIs. Enhanced capacity additions under the PLI schemes are anticipated to meet these requirements. Imports of bulk drugs & intermediates into India have experienced a notable 12% decline in the first three quarters of the fiscal year 2023-24. The data provided by the DGCIS reveals that, from April to December 2023, the imports totalled approximately 2.95 lakh MTs, valued at $3 billion. In comparison, the same period in the previous fiscal year recorded 2.92 lakh metric tonnes, valued at $3.41 billion. Importantly, imports from China exhibited a more significant #decline of 9.45% during this period, reflecting the country's reduced contribution to the Indian pharmaceutical supply chain. The value of imports from China dropped to $2.15 billion, down from $2.38 billion in the corresponding nine months of the previous fiscal year. For the quarter spanning October to December 2023, bulk drugs and intermediates imports reported a substantial 33.3% decline at $770.96 million, in contrast to the $1.16 billion recorded in the same period of the preceding year. Quantity-wise, there was a corresponding drop of around 32%, with imports totalling 69,170 metric tonnes compared to 1.01 lakh metric tonnes during the same quarter in the previous fiscal year. Imports from China during the last quarter of 2023 declined by approximately 30.4% to $550.32 million, down from $790.35 million in the October to December 2022 period. Quantity-wise, imports decreased from 77,915 metric tonnes to 51,126 metric tonnes during the comparable period. The Indian government has been actively working to reduce dependence on bulk drug imports, particularly from China. Initiatives such as the production-linked incentive (PLI) scheme aim to promote domestic manufacturing of critical key starting materials (KSMs), drug intermediates, and active pharmaceutical ingredients (APIs). Additionally, support for bulk drug parks in Gujarat, Himachal Pradesh, and Andhra Pradesh, with a financial outlay of Rs. 3,000 crore underscores the #commitment to #fostering domestic production through common infrastructure facilities. The completion of projects under the PLI scheme is anticipated to positively impact the industry's reliance on imports. By the end of FY24, the dependency on imports is projected to decrease to 69%, with a further reduction to around 65% as major projects become operational in the fourth quarter of FY24, and additional projects commence in FY25.

Why India's pharma industry must prioritise patient safety and innovation to sustain momentum? As the 'Pharmacy of the World' and a leading producer of generic drugs, India has gained international recognition for meeting its own needs and those of many other nations. India's pharmaceutical industry believes that its goal to move up to the top 10 in terms of value by 2030 is achievable, given it currently 14th ranking the world. However, addressing the challenges of counterfeit and inferior pharmaceuticals is extremely difficult for the pharmaceutical sector and its regulators. https://lnkd.in/g7h9Dzkf

🌍 India's Pharmaceutical Export Growth: A Strong Start to 2024 Exciting news for the Indian pharmaceutical industry as it kicks off 2024 with robust export growth! 🚀 1. Exports Surge: India's pharmaceutical exports are expected to reach $27 billion in FY24, marking a significant increase driven by a rising demand for generic drugs, vaccines, and biosimilars globally​. 2. Government Support: The Indian government is set to enhance its Production-Linked Incentive (PLI) scheme and provide further tax breaks and funding for innovation. These measures aim to bolster R&D and promote the manufacturing of high-quality pharmaceutical products​. 3. Addressing Challenges: Despite regulatory and logistical hurdles, including compliance with international standards and infrastructure limitations, Indian pharma companies are investing in technology and quality improvements to maintain their competitive edge​. 4. Future Outlook: With a focus on innovation and quality, the Indian pharmaceutical industry aims to grow to $120-130 billion by 2030, making significant strides in the global healthcare sector​. The collaborative efforts between the government and the private sector, along with strategic investments in R&D and infrastructure, are paving the way for sustained growth and leadership in the global pharmaceutical market. I'm always looking to connect with professionals in the pharmaceutical industry for strategic partnerships and how we can work together! Let's collaborate and share insights on supply chain innovations and challenges. Feel free to connect, engage and share your thoughts and experiences on these updates! RAYCE PHARMA #PharmaExports #IndiaPharma #HealthcareInnovation #GlobalMarket #2024Trends #PharmaBuyers #PharmaSuppliers #PharmaProcurement #PharmaSourcing #PharmaDistribution #PharmaLogistics #PharmaNetworking #PharmaTrade #PharmaSales #PharmaWholesale #Globalhealth #Pharmaceuticals #API #Excipients #Intermediates #Export #Import #Buyers #Suppliers #CPHI #Pharmexcil #Health #Logistics #RaycePharma

Top 10 Pediatric Pharma Companies In India If you want your business to succeed, you need to target the right consumers with our products and franchise services. Today’s consumers are more knowledgeable and discerning than ever before. If you cater to younger consumers, it’s important that you find a company that specializes in meeting the unique needs of younger consumers. Working with one of the Top 10 PCD pharma companies in India that specializes in pediatric medicines can streamline operations and save your business time and money in the long run. https://lnkd.in/g3fYw_NC

Thoughts on this? >> Rajnath Singh Declares Assets Worth Rs 7.36 Crore In Lok Sabha Election Affidavit >> Comment below! >>> lqventures.com #digitalhealth #socialmedia #digitalmarketing #healthtech #AI #mhealth #IoT #industry40

Exclusive Range Of Products For Pharma Franchise In India 

The OPPI, the Organization of Pharmaceutical Producers of India, which represents prominent MNCs, has requested exemptions from government set price control for patented and orphan drugs. It argues that price control can stymie innovation. The NPPA had last year, in May, notified that the ceiling price of drugs going off patent will be reduced to 50%, with a view to curb profiteering by companies. The new prices were to be fixed after a year of patent expiry after researching market data. Earlier the MNCs had an option to continue with the same price till generic versions of their drug product hit the market. #pharma #pricerelief #oppi #nppa https://lnkd.in/dXNttQsh

change is in the wind sir

Thoughts on this? >> Patanjali Misleading Ads Case: Supreme Court Rebukes IMA President, Refuses To Accept His Apology >> Comment below! >>> lqventures.com #digitalhealth #socialmedia #digitalmarketing #industry40 #AI #healthtech #IoT #mhealth

Thoughts on this? >> India Grapples With 'Unfavourable' Global Factors In Growth Push, Says CEA Nageswaran >> Comment below! >>> lqventures.com #digitalhealth #socialmedia #digitalmarketing #AI #healthtech #IoT #industry40 #mhealth

Thoughts on this? >> IMD Predicts Rain In Odisha As Low Pressure Area Forms Over Bay Of Bengal >> Comment below! >>> lqventures.com #digitalhealth #socialmedia #digitalmarketing #industry40 #mhealth #AI #healthtech #IoT

Issue of presence of DEG / EG in Cough syrups still haunting Indian Pharma ! 9 out of 7087 samples picked up by regulators failed with DEG / EG presence ! Pharma companies managements have to be fully alert to avoid repeatation of recent epidodes! Dt : 23.7.2024. ****** - After Gambia and Uzbekistan bad experiences , Indian regulator and Industry took strong note of the incidents and taking care to test Propylene Glycol ( used as diluent in cough syrups ) for presence of DEG / EG impurities . - DCG I and DGFT have also made it mandatory to get the cough syrup samples tested in NABL accredited Govt labs . DGFT made it compulsory to submit CoA copies for all exported cough syrup consignments. - It is surprising to note that 9 samples out of 7035 samples picked up by regulators failed for these toxic / poisonous chemicals. - it is good that samples are being regularly lifted from cough syrup manufacturers and also from PG manufacturers and suppliers. - Let us hope that with full awareness by Pharma industry by now, it would be 100% compliant for absence of toxic ingredients in future pick ups !